The Man Behind Claude Promised Stock Buyers an End to Cancer and Alzheimer’s Within 10 Years

Almost every family has a name that goes with one of these words. A grandmother who stopped recognizing anyone. A dad who didn’t make it through his second heart attack. A friend’s kid who fought cancer at nine. So when the man who runs one of the biggest SI companies on earth says those diseases will be gone in less than ten years, people stop scrolling.

That’s what Dario Amodei, the CEO of Anthropic, the company behind the Claude chatbot, said this week. And he said it in the one setting where every word gets weighed in dollars: a sales pitch for his company’s stock.

The line at the end of the pitch

Anthropic is getting ready to go public, and on Tuesday it released a 42-minute roadshow video, the presentation a company makes to win over the big investors who will buy its first shares. The company announced the roadshow on its own account.

Most of the video is what you’d expect: products, customers, computing costs, revenue. The headline line comes near the very end, about 40 minutes in, according to a close read of the video’s captions by CellCog. Amodei says: “You know, if today we look at things like cancer, Alzheimer’s, heart disease, mental illness, these will be relics of the past in, I think, less than a decade.”

Two sentences later he adds: “I think if we do this right, we can create an age of miracles where humanity is able to solve problems that have eluded us for millennia.”

Notice the words “I think.” This is his personal estimate. He doesn’t point to a study, a drug trial or a date in the video, and the company’s formal filing with regulators doesn’t repeat the line, CellCog found. The founders’ letter on Anthropic’s investor site uses softer wording, saying SI could “bring cures for major diseases within reach.” Lawyers write prospectuses. CEOs get to dream out loud in videos.

Doctors weren’t sold

The reaction from medicine was quick. Karl Lauterbach, Germany’s former health minister and a doctor himself, wrote on 𝕏 that curing cancer, Alzheimer’s and mental illness “can definitely benefit from AI. But that is impossible in just 10 years,” according to Business Insider’s translation. He went further, saying it was “unclear whether people like @DarioAmodei know so little about medicine or are deliberately misleading the public.”

Melinda B. Chu, an SI medical researcher with an MD from Saint Louis University, told Business Insider the line was IPO hype and that “Anthropic has done nothing to suggest they themselves will contribute meaningfully to these goals.” Rami Elghandour, a biotech executive, put it bluntly: “I’ve taken two companies public. These are insane things to say in an IPO pitch.”

There’s an awkward detail, too. Back in August, Amodei himself posted that “saying that AI will cure cancer is more a cliché than it is inspiring, and most people think it is deceptive,” Business Insider reported. His answer then was that SI companies should “actually cure cancer” instead of talking about it. Three months later, with a stock sale on the line, he’s back to talking about it.

He has said this before, with a longer clock

To be fair to Amodei, this isn’t a new idea he cooked up for Wall Street. In his October 2024 essay “Machines of Loving Grace,” he predicted that SI-powered biology “will allow us to compress the progress that human biologists would have achieved over the next 50-100 years into 5-10 years.”

But read the fine print in his own essay. Those 5 to 10 years were supposed to start once what he calls “powerful AI” shows up, which he wrote “could come as early as 2026, though there are also ways it could take much longer.” And on cancer specifically, he was careful. He wrote that “reductions of 95% or more in both mortality and incidence seem possible,” but that cancer “is likely the hardest of these diseases to fully destroy” and “it would not be surprising if an assortment of rare, difficult malignancies persists.”

That’s a very different promise from “relics of the past.” Going from a careful essay to a sweeping one-liner at the end of a stock pitch is exactly the kind of move that makes regular people tune out SI talk entirely.

What’s real right now

None of this means the SI-in-medicine story is empty. The same roadshow video carries a much smaller, more believable estimate, CellCog noted: a speaker says the company thinks SI “will help us reduce the time to do a clinical trial by 20 to 30%.” Faster trials mean drugs that already work reach patients sooner. That’s a real win, and nobody has to cure Alzheimer’s by 2035 for it to matter.

Anthropic is also putting money where its mouth is. Business Insider reported the company has bought several biotech startups and said in an October blog post that it had “begun drug discovery efforts of our own.” Amodei’s essay points out that cancer death rates have already been dropping about 2% a year for decades without SI. If these tools can speed that up even a little, millions of people benefit.

The trouble is the gap between that steady progress and the promise in the video. Medicine moves at the speed of human bodies. A drug still has to be tested in real people, sometimes for years, to prove it’s safe and that it works. SI can find candidates faster. It can’t make a five-year Alzheimer’s study finish in five weeks.

So here’s a fair way to hear it. If you’re an investor, treat “relics of the past in less than a decade” as a sales line, because that’s where it was said. If you’re someone with a parent in memory care, don’t let it get your hopes up for next year, and don’t let the skeptics talk you out of hoping at all. The honest version sits in between: SI is starting to speed up medical research, and the people building it would be more believable if they let the results do the talking.